Paratek Pharmaceuticals to present data on lead commercial product, shares up
23/09/2021 23:14
** Shares of biopharma PRTK.O up 9% at $5.29 in trading
after the bell
** Co says will present data from the NUZYRA clinical and
microbiology programs this month urn:newsml:reuters.com:*:nGNX2V5X4X
** NUZYRA is PRTK's lead commercial product for treatment of
bacterial pneumonia and acute skin infections
** Stock has dropped nearly 22% this year
(Reporting by Niket Nishant in Bengaluru)
((Niket.Nishant@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million